Hepatic Conditions and Medical Cannabis
-
Overview
Estimated to affect over a billion people globally, hepatitis is a major global health crisis. Characterised by inflammation of the liver, hepatitis is responsible for severe consequences including liver damage, failure and death.¹
But it is preventable and treatable. The World Health Organisation (WHO) and its member states (including Australia) have pledged to reduce hepatitis infections by 90% and hepatitis B and C related deaths by 65% by 2030 through vaccination, diagnostic testing, medication, and educational initiatives.¹‚²
The use of medical cannabis in the treatment of hepatitis symptoms is a relatively new and evolving area of research, with findings that have sometimes been contradictory.
While more research is needed to reach definitive conclusions, early evidence suggests that medical cannabis may have the potential to improve the quality of life for those living with hepatitis by addressing primary and secondary symptoms.
Preview this module by watching the video above.
Estimated Duration: 1.5 hours
Access Duration: 12 months from date of purchase
Learning Outcomes
Upon completion of this module, you’ll be able to:
- Describe the prevalence, pathogenesis, pathophysiology, symptoms and impacts of, and diagnostic methods for hepatitis and its subtypes
- Identify common hepatitis treatment interventions and explain their pharmacology
- Explain how medical cannabis treatment may benefit people with hepatitis
- Identify and explain potential risks and clinical considerations when recommending medical cannabis treatment for people with hepatitis
References
¹ World Health Organisation. Hepatitis. www.who.int. Published 2024. Accessed August 30, 2024. https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030
² Coalition for Global Hepatitis Elimination. About Hepatitis Elimination. CGHE. Accessed August 30, 2024. https://www.globalhep.org/about/about-hepatitis-elimination#:~:text=In%202016%2C%20the%20World%20Health
Overview
Estimated to affect over a billion people globally, hepatitis is a major global health crisis. Characterised by inflammation of the liver, hepatitis is responsible for severe consequences including liver damage, failure and death.¹
But it is preventable and treatable. The World Health Organisation (WHO) and its member states (including Australia) have pledged to reduce hepatitis infections by 90% and hepatitis B and C related deaths by 65% by 2030 through vaccination, diagnostic testing, medication, and educational initiatives.¹‚²
The use of medical cannabis in the treatment of hepatitis symptoms is a relatively new and evolving area of research, with findings that have sometimes been contradictory.
While more research is needed to reach definitive conclusions, early evidence suggests that medical cannabis may have the potential to improve the quality of life for those living with hepatitis by addressing primary and secondary symptoms.
Preview this module by watching the video above.
Estimated Duration: 1.5 hours
Access Duration: 12 months from date of purchase
Learning Outcomes
Upon completion of this module, you’ll be able to:
- Describe the prevalence, pathogenesis, pathophysiology, symptoms and impacts of, and diagnostic methods for hepatitis and its subtypes
- Identify common hepatitis treatment interventions and explain their pharmacology
- Explain how medical cannabis treatment may benefit people with hepatitis
- Identify and explain potential risks and clinical considerations when recommending medical cannabis treatment for people with hepatitis
References
¹ World Health Organisation. Hepatitis. www.who.int. Published 2024. Accessed August 30, 2024. https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030
² Coalition for Global Hepatitis Elimination. About Hepatitis Elimination. CGHE. Accessed August 30, 2024. https://www.globalhep.org/about/about-hepatitis-elimination#:~:text=In%202016%2C%20the%20World%20Health